Subunit vaccination of mice against new world cutaneous leishmaniasis: Comparison of three proteins expressed in amastigotes and six adjuvants

Infection and Immunity

Volumn 68, Issue 3, 2000, Pages 1328-1336

  Aebischer, Toni ^a   Wolfram, Markus ^a   Patzer, Silke I ^a   Ilg, Thomas ^a   Wiese, Martin ^a   Overath, Peter ^a  

^a MAX PLANCK INST FÜR BIOLOGIE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CD4 ANTIGEN; CORYNEBACTERIUM PARVUM EXTRACT; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; LEISHMANIA VACCINE; PHOSPHORYL LIPID A; QS 21; RECOMBINANT PROTEIN;

AMASTIGOTE; ANIMAL CELL; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; FEMALE; HELPER CELL; LEISHMANIA MEXICANA; LEISHMANIASIS; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN LEISHMANIASIS; T LYMPHOCYTE; VACCINATION;

EID: 0033953695     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.68.3.1328-1336.2000     Document Type: Article

References (73)

1. Aebischer, T. 1994. Recurrent cutaneous leishmaniasis: a role for persistent parasites? Parasitol. Today 10:25-28.
2. Aebischer, T., L. Morris, and E. Handman. 1994. Intravenous injection of irradiated Leishmania major into susceptible BALB/c mice: immunization or protective tolerance. Internat. Immunol. 6:1535-1543.
3. Afonso, L. C. C., T. M. Scharton, L. Q. Vieira, M. Wysocka, G. Trinchieri, and P. Scott. 1994. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 263:235-237.
4. Afonso, L. C. C., and P. Scott. 1993. Immune response associated with susceptibility of C57BL/10 mice to Leishmania amazonensis. Infect. Immun. 61:2952-2959.
5. Alexander, J. 1982. A radioattenuated Leishmania major vaccine markedly increases the resistance of CBA mice to subsequent infection with Leishmania mexicana mexicana. Trans. R. Soc. Trop. Med. Hyg. 76:646-649.
6. Alexander, J., G. H. Coombs, and J. Mottram. 1998. Leishmania mexicana cysteine proteinase-deficient mutants have attenuated virulence for mice and potentiate a Th1 response. J. Immunol. 161:6794-6801.
7. Atkins, M. B., M. J. Robertson, M. Gorodon, M. T. Lotze, M. DeCoste, J. S. DuBois, J. S. Ritz, A. B. Sandler, A. B. Edington, P. D. Garzone, J. W. Mier, C. M. Canning, L. Battiato, H. Tahara, and M. L. Sherman. 1997. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin. Cancer Res. 3:409-417.
8. Bahr, V., Y.-D. Stierhof, T. Ilg, M. Demar, M. Quinten, and P. Overath. 1993. Expression of lipophosphoglycan, high-molecular-weight phosphoglycan and glycoprotein 63 in promastigotes and amastigotes of Leishmania mexicana. Mol. Biochem. Parasitol. 58:107-122.
9. Castes, M., J. Blackwell, D. Trujillo, S. Formica, M. Cabrera, G. Zorrilla, A. Rodas, P. L. Castellanos, and J. Convit. 1994. Immune response in healthy volunteers vaccinated with killed leishmanial promastigotes plus BCG. I: Skin-test reactivity, T-cell proliferation and interferon-γ production. Vaccine 12:1041-1051.
10. Champsi, J., and D. McMahon-Pratt. 1988. Membrane glycoprotein M-2 protects against Leishmania amazonensis infection. Infect. Immun. 52:3272-3279.
11. Connell, N. D., E. Medina-Acosta, W. R. McMaster, B. R. Bloom, and D. Russell. 1993. Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guérin expressing the Leishmania surface proteinase gp63. Proc. Natl. Acad. Sci. USA 90:11473-11477.
12. Convit, J. 1996. Leishmaniasis: immunological and clinical aspects and vaccines in Venezuela. Clin. Dermatol. 14:479-487.
13. Convit, J., P. L. Castellanos, M. Ulrich, M. Castes, A. Rondon, M. E. Pinardi, N. Rodriguez, B. R. Bloom, S. Formica, and L. Valecillos. 1989. Immunotherapy of localized, intermediate and diffuse forms of American cutaneous leishmaniasis. J. Infect. Dis. 160:104-115.
14. Convit, J., P. L. Castellanos, A. Rondon, M. E. Pinardi, M. Ulrich, M. U. M. Castes, B. Bloom, and L. Garcia. 1987. Immunotherapy versus chemotherapy in localized cutaneous leishmaniasis. Lancet i:401-405.
15. Donnelly, J. J., J. B. Ulmer, J. W. Shiver, and M. A. Liu. 1997. DNA vaccines. Annu. Rev. Immunol. 15:617-648.
16. Grimaldi, G., Jr. 1995. Meetings on vaccine studies towards the control of leishmaniasis. Mem. Inst. Oswaldo Cruz. 90:553-556.
17. Gurunathan, S., C. Prussin, D. L. Sacks, and R. A. Seder. 1998. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. Nat. Med. 4:1409-1415.
18. Gurunathan, S., D. L. Sacks, D. R. Brown, S. L. Reiner, H. Charest, N. Glaichenhaus, and R. A. Seder. 1997. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J. Exp. Med. 186:1137-1147.
19. Handman, E. 1997. Leishmania vaccines: old and new. Parasitol. Today 13:236-238.
20. Handman, E., F. M. Symons, T. M. Baldwin, J. M. Curtis, and J.-P. Y. Scheerlinck. 1995. Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a Th1 type of immune response. Infect. Immun. 63:4261-4267.
21. Heinzel, F. P., D. S. Schoenhaut, R. M. Rerko, L. E. Rosser, and M. K. Gately. 1993. Recombinant interleukin 12 cures mice infected with Leishmania major. J. Exp. Med. 177:1505-1509.
22. Hoffman, S. L., R. Edelman, J. P. Bryan, I. Schneider, J. Davis, M. Sedegah, D. Gordon, P. Church, M. Gross, C. Siverman, et al. 1994. Safety, immunogenicity, and efficacy of a malaria sporozoite vaccine administered with monophosphoryl lipid A, cell wall skeleton of mycobacteria, and squalane as adjuvant. Am J. Trop. Med. Hyg. 51:603-612.
23. Howard, J. G., S. Nicklin, C. Hale, and F. Y. Liew. 1982. Prophylactic immunization against experimental leishmaniasis. I. Protection induced in mice genetically vulnerable to fatal Leishmania tropica infection. J. Immunol. 129:2002-2012.
24. Ilg, T., M. Fuchs, V. Gnau, M. Wolfram, D. Harbecke, and P. Overath. 1994. Distribution of parasite cysteine proteinases in lesions of mice infected with Leishmania mexicana amastigotes. Mol. Biochem. Parasitol. 67:193-203.
25. Ilg, T., D. Harbecke, and P. Overath. 1993. The lysosomal gp63-related protein in Leishmania mexicana amastigotes is a soluble metalloproteinase with an acidic pH optimum. FEBS Lett. 327:103-107.
26. Jaffe, C. L., N. Rachamim, and R. Sarfstein. 1990. Characterization of two proteins from Leishmania donovani and their use for vaccination against visceral leishmaniasis. J. Immunol. 144:699-706.
27. Jardim, A., J. Alexander, H. S. Teh, D. Ou, and R. W. Olafson. 1990. Immunoprotective Leishmania major synthetic T cell epitopes. J. Exp. Med. 172:645-648.
28. Lanza, P., R. B. Moss, W. Giermakowska, R. B. Hancock, S. P. Richieri, G. Theofa, F. C. Jensen, P. L. Salk, and D. J. Carlo. 1998. Whole-killed gp120-depleted HIV-1 antigen in a murine model for prophylactic vaccination. Vaccine 16:727-731.
29. Liew, F. V., C. Hale, and J. G. Howard. 1985. Prophylactic immunization against experimental leishmaniasis. IV. Subcutaneous immunization prevents the induction of protective immunity against fatal Leishmania major infection. J. Immunol. 135:2095-2101.
30. McMahon-Pratt, D., D. Rodriguez, J.-R. Rodriguez, Y. Zhang, K. Manson, C. Bergman, L. Rivas, J. F. Rodriguez, K. L. Lohman, N. H. Ruddle, and M. Esteban. 1993. Recombinant vaccinia viruses expressing GP46/M-2 protect against Leishmania infection. Infect. Immun. 61:3351-3359.
31. Medina-Acosta, E., R. E. Karess, and D. G. Russell. 1993. Structurally distinct genes for the surface protease (gp63) of Leishmania mexicana are developmental regulated. Mol. Biochem. Parasitol. 57:31-46.
32. Medina-Acosta, E., R. E. Karess, H. Schwarz, and D. G. Russell. 1989. The promastigote surface protease (gp63) of Leishmania is expressed but differentially processed and localized in the amastigote stage. Mol. Biochem. Parasitol. 37:253-274.
33. Menz, B., G. Winter, T. Ilg, F. Lottspeich, and P. Overath. 1991. Purification and characterization of a membrane-bound acid phosphatase of Leishmania mexicana. Mol. Biochem. Parasitol. 47:101-108.
34. Mitchell, G. F., and E. Handman. 1987. Heterologous protection in murine cutaneous leishmaniasis. Immunol. Cell Biol. 65:387-392.
35. Modabber, F. 1989. Experience with vaccines against cutaneous leishmaniasis: of men and mice. Parasitology 98:S49-S60.
36. Modabber, F. 1995. Vaccines against leishmaniasis. Ann. Trop. Med. Parasitol. 89:83-88.
37. Momeni, A. Z., T. Jalayer, M. Emamjomeh, A. Khamesipour, F. Zicker, R. L. Ghassemi, Y. Dowlati, I. Sharifi, M. Aminjavaheri, A. Shafiei, M. H. Alimohammadian, R. Hashemi-Fesharki, K. Nasseri, T. Godal, P. G. Smith, and F. Modabber. 1998. A randomized, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran. Vaccine 17:465-472.
38. Mottram, J. C., D. R. Books, and G. H. Coombs. 1998. Roles of cysteine proteinases of trypanosomes and Leishmania in host-parasite interactions. Curr. Opin. Microbiol. 1:455-460.
39. Mottram, J. C., A. E. Souza, J. E. Hutchison, R. Carter, M. J. Frame, and G. H. Coombs. 1996. Evidence from disruption of the lmcpb gene array of Leishmania mexicana that cysteine proteinases are virulence factors. Proc. Natl. Acad. Sci. USA 93:5008-6013.
40. Mougneau, E., F. Altare, A. E. Wakil, S. Zheng, T. Coppola, Z.-E. Wang, R. Waldmann, R. M. Locksley, and N. Glaichenhaus. 1995. Expression cloning of a protective Leishmania antigen. Science 268:563-566.
41. Overath, P., and Aebischer, T. 1999. Antigen presentation by macrophages harboring intravesicular pathogens. Parasitol. Today 15:325-332.
42. Patzer, S. 1994. Leishmania mexicana: Expression in E. coli und Reinigung des Amastigoten-spezifischen GP63 und Isolierung der membrangebundenen sauren Phosphatase. Diploma thesis. Universität Tübingen, Tübingen, Germany.
43. Rachamim, N., and C. L. Jaffe. 1993. Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis. J. Immunol. 150:2322-2331.
44. Read Kensil, C. 1996. Saponins as vaccine adjuvants. Crit. Rev. Ther. Drug Carrier Syst. 13:1-55.
45. Read Kensil, C., and R. Kammer. 1998. QS-21: a water-soluble triterpene glycoside adjuvant. Exp. Opin. Investig. Drugs 7:1475-1482.
46. Reiner, S. L., and R. M. Locksley. 1995. The regulation of immunity to Leishmania major. Annu. Rev. Immunol. 13:151-177.
47. Rickman, L. S., D. M. Gordon, R. Wistar, Jr., U. Krzych, M. Gross, M. R. Hollingdale, J. E. Egan, J. D. Chulay, and S. L. Hoffman. 1991. Use of adjuvant containing mycobacterial cell-wall skeleton, monophosphoryl lipid A, and squalane in malaria circumsporozoite protein vaccine. Lancet 337: 998-1001.
48. Rivier, D., R. Shah, P. Bovay, and J. Mauel. 1993. Vaccine development against cutaneous leishmaniasis. Subcutaneous administration of radioattenuated parasites protects CBA mice against virulent Leishmania major challenge. Parasitol. Immunol. 15:75-84.
49. Roberts, M., J. Alexander, and J. M. Blackwell. 1989. Influence of Lsh, H-2, and an H-11-linked gene on visceralization and metastasis associated with Leishmania mexicana infection in mice. Infect. Immun. 57:875-881.
50. Russell, D. G., and J. Alexander. 1988. Effective immunization against cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes. J. Immunol. 140:1274-1279.
51. Sasaki, S., K. Sumino, K. Hamajima, J. Fukushima, N. Ishii, S. Kawamoto, H. Mohri, C. Read Kensil, and K. Okuda. 1998. Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes. J. Virol. 72:4931-4939.
52. Satoskar, A., H. Bluethmann, and J. Alexander. 1995. Disruption of the murine interleukin-4 gene inhibits disease progression during Leishmania mexicana infection but does not increase control of Leishmania donovani infection. Infect. Immun. 63:4894-4899.
53. Schneider, P., C. Bordier, and R. Etges. 1992. Membrane proteins and enzymes of Leishmania. Sub-cell. Biochem. 18:39-72.
54. Sjölander, A., T. M. Baldwin, J. M. Curtis, and E. Handman. 1998. Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response are required for generation of immunity to leishmaniasis. J. Immunol. 160:3949-3957.
55. Soong, L., S. Monroe Duboise, P. Kima, and D. McMahon-Pratt. 1995. Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis. Infect. Immun. 63:3559-3566.
56. Stenger, S., N. Donhauser, H. Thüring, M. Röllinghoff, and C. Bogdan. 1996. Reactivation of latent leishmaniasis by inhibition of inducible nitric oxide synthase. J. Exp. Med. 183:1501-1514.
57. Stover, C. K. 1994. Recombinant vaccine delivery systems and encoded vaccines. Curr. Opin. Immunol. 6:568-571.
58. Sypek, J. P., C. L. Chung, S. E. H. Mayor, J. M. Subramanyam, S. J. Goldman, D. S. Sieburth, S. F. Wolf, and R. G. Schaub. 1993. Resolution of cutaneous leithmaniasis: interleukin 12 initiates a protective T helper type 1 immune response. J. Exp. Med. 177:1797-1802.
59. Titus, R. G., F. J. Gueiros-Filho, L. A. R. de Freitas, and S. M. Beverley. 1995. Development of a safe live Leishmania vaccine line by gene replacement. Proc. Natl. Acad. Sci. USA 92:10267-10271.
60. Ulrich, J. R., J. L. Cantrell, G. L. Gustafson, K. R. Myers, J. A. Rudbach, and J. R. Hiernaux. 1990. The adjuvant activity of monophosphoryl lipid A, p. 137-143. In D. R. Spriggs and W. C. Koff (ed.), Topics in vaccine adjuvant research. CRC Press, Boca Raton, Fla.
61. Ulrich, J. T., and K. R. Myers. 1995. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. Pharmacol. Biotechnol. 6:495-524.
62. Vremec, D., M. Zorbas, R. Scollay, D. J. Saunders, C. F. Aradavin, L. Wu, and K. Shortman. 1992. The surface phenotype of dendritic cells purified from mouse thymus and spleen: investigation of the CD8 expression by a subpopulation of dendritic cells. J. Exp. Med. 176:47-58.
63. Walker, P. S., T. Scharton-Kersten, E. D. Rowton, U. Hengge, A. Bouloc, M. C. Udey, and J. C. Vogel. 1998. Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis. Hum. Gene Ther. 9:1899-1907.
64. Walton, B. C. 1987. American cutaneous and mucocutaneous leishmaniasis, p. 637-664. In W. Peters and R. Killick-Kendrick (ed.). The leishmaniases in biology and medicine, vol. 2. Clinical aspects and control. Academic Press, London, England.
65. Wiese, M. 1998. A mitogen-activated protein (MAP) kinase homologue of Leishmania mexicana is essential for parasite survival in the infected host. EMBO J. 17:2619-2628.
66. Wiese, M., O. Berger, Y.-D. Stierhof, M. Wolfram, M. Fuchs, and P. Overath. 1996. Gene cloning and cellular localization of a membrane-bound acid phosphatase of Leishmania mexicana. Mol. Biochem. Parasitol. 82:153-165.
67. Wolfram, M. 1996. Antigenpräsentation durch Leishmania mexicana-infizierte Makrophagen. Ph.D. dissertation. Universität Tübingen, Tübingen, Germany.
68. Wolfram, M., M. Fuchs, M. Wiese, Y.-D. Stierhof, and P. Overath. 1996. Antigen presentation by Leishmania mexicana-infected macrophages: activation of helper T cells by a model parasite antigen secreted into the parasitophorous vacuole or expressed on the amastigote surface. Eur. J. Immunol. 26:3153-3162.
69. Wolfram, M., T. Ilg, J. C. Mottram, and P. Overath. 1995. Antigen presentation by Leishmania mexicana-infected macrophages: activation of helper T cells specific for amastigote cysteine proteinases requires intracellular killing of the parasites. Eur. J. Immunol. 25:1094-1100.
70. Xu, D., and F. Y. Liew. 1994. Genetic vaccination against leishmaniasis. Vaccine 12:1534-1536.
71. Xu, D., and F. Y. Liew. 1995. Protection against leishmaniasis by injection of DNA encoding a major surface glycoprotein, gp63, of L. major. Immunology 84:173-176.
72. -). Immunology 85:1-7.
73. -) vaccine expressing a major leishmanial surface protein (gp63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis. J. Immunol. 145:2281-2285.